




The relative strengths and weaknesses of Urovant Sciences Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urovant Sciences Ltd compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 10% points. The greatest weakness of Urovant Sciences Ltd is the variable Research and Development, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 157% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	12,390
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,910
Liabilities, Non-Current	0
Other Assets	84
Other Compr. Net Income	32
Other Expenses	75
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	510
Research and Development	32,359
Selling, General and Administrative Expense	4,640

Output Variable	Value in 1000 USD
Assets	12,984
Liabilities	5,910
Expenses	37,074
Revenues	0
Stockholders Equity	7,074
Net Income	-37,074
Comprehensive Net Income	-37,058
BaseVar	28,000
ECR before Limited Liability	-229%
Economic Capital Ratio	93%